According to a story from the Malvern Daily Record, the biotechnology company Exelixis, Inc. has recently announced that its partner company Ipsen BioPharmaceuticals Canada Inc. has had its drug cabozantinib…
According to a story from BioPortfolio, the biotechnology company Tiziana Life Sciences plc has announced the release of preliminary topline data findings from its phase 2a clinical trial, which tested…
The FDA has just recently approved CYRAMZA as a treatment for those with hepatocellular carcinoma (HCC), who have been treated with sorafenib, and who have ≥400 ng/mL of alpha-fetoprotein (AFP).…
According to a story from finanzen.ch, the pharmaceutical company Eisai, Inc. announced that that company presented a total of four abstracts which were related to a Phase 3 clinical trial…
According to a story from BioPortfolio, the biotechnology company Tiziana Life Sciences plc recently announced encouraging results from an interim safety review of the company's Phase 2a clinical trial. This…
According to an article from Global Banking & Financing Review, the California-based pharmaceutical company Exelixis, Inc. has announced the FDA's approval of their drug Cabometyx (cabozantinib) for patients previously diagnosed…
According to a story from BioSpace, the biotechnology company Tiziana Life Sciences Plc has recently announced that participant enrollment in its Phase 2a clinical trial has finished. This clinical trial…
According to a story from bioportfolio.com, the biopharmaceutical company Eureka Therapeutics recently released the results of the proof of concept trial for its experimental T-cell therapy ET140202 as a treatment…
According to a story from the St. Helens Star, Amanda Sackville-Wiggins was diagnosed with hepatocellular carcinoma, a rare type of liver cancer, just after her 21st birthday. The cancer was…
According to a story from Financial Buzz, the drug development company Eisai and Merck recently announced that their cancer drug lenvatinib, marketed as LENVIMA,® has gained marketing approval from the…
Meet Andrea Wilson Woods (pictured below with her little sister); an author, public speaker, career coach, organization founder, and patient advocate. In her early twenties, Andrea became the legal guardian…
According to Phys.org, a group of researchers at the Medical University of South Carolina recently discovered exciting news regarding cancer cells in humans. Specifically, these scientists have found that these…
According to medicalxpress.com, Hepatocellular carcinoma is the third leading cause of cancer deaths in the world. It is also the most common form of liver cancer. New research from a…
Doctors told Samantha Youakim she had hepatocellular carcinoma when she was 10 years old. As a result of this rare form of liver cancer, the experts told her she’d only…
According to a story from brightsurf.com, a recent research finding suggests that fibrolamellar hepatocellular carcinoma, a rare form of liver cancer that can occur in children, is capable of metastasis…
According to an article from kait8.com, the pharmaceutical company Yisheng Biopharma announced that YS-ON-001, a leading candidate for the company, received Orphan Drug Designation from the U.S. Food and Drug…
Hepatocellular carcinoma is a form of cancer that starts out in the liver. As far as cancers that begin in the liver, it's common, but it's still important to differentiate it…
Patients with hepatocellular carcinoma can look forward to the FDA accelerated approval of nivolumab (Opdivo) after prior sorafenib (Nexavar) treatment. Hepatocellular carcinoma is a common form of liver cancer that cannot be…
Onxeo has recently received the 10th unanimous recommendation from the Data Safety Monitoring Board to continue with the Phase 3 study (coined ReLive) of Livatag®. Livatag® is designed for use…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
